Regeneron stock holds above $826 as FDA approval and lawsuit reshape risk picture
Published on 08/21/2026 at 12:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron Pharmaceuticals Inc. (US75886F1075) stock is trading in the mid-$820s, with a last close of $826.64 on August 20, 2026, as investors weigh a new FDA approval for the rare-disease drug Pasatru against a recently filed securities class action lawsuit over a failed melanoma trial. Recent market data show the shares modestly higher year-to-date while valuation and risk perceptions are shifting.
Shares consolidate after recent volatility
Per a consensus overview updated on August 20, 2026, Regeneron stock last closed at $826.64 on the Cboe venue, with a quoted level of $826.24 earlier in the session and a 5-day change of -1.81%. The same overview indicates the shares are up 2.53% since the start of 2026 and 6.95% over the past 12 months, suggesting that despite recent swings the longer-term trend remains positive.
Several institutional investors disclosed new or increased positions in Regeneron on August 21, 2026. One filing describes the shares opening at $826.64 on Nasdaq on that date and mentions that the company currently pays a quarterly dividend of $0.94 per share, implying an annualized payout of $3.76 and a dividend yield of 0.5% at recent prices. The institutional update also notes a consensus rating described as Moderate Buy and an average published price target of $801.70, placing the current share price modestly above that target.
FDA clears Pasatru for ultra-rare bone disease
A major recent catalyst for Regeneron is US Food and Drug Administration approval of Pasatru, a monoclonal antibody treatment for adults with fibrodysplasia ossificans progressiva (FOP), a degenerative ultra-rare bone disease. Coverage on August 20, 2026 reports that the FDA decision makes Pasatru the first approved therapy for FOP aimed at reducing new heterotopic ossification lesions and flare-ups in this patient group. One analysis of the approval highlights that Pasatru opens a new therapeutic franchise for Regeneron beyond its existing ophthalmology and immunology portfolio.
Detailed reporting on the approval adds that Pasatru will have an average annual per-patient list price of $1.4 million based on clinical-study enrollment patterns, underscoring the high-revenue potential of even a small patient pool. The FDA clearance article notes that Pasatru targets FOP by modulating pathways associated with abnormal bone formation and is expected to compete with an earlier drug for the same indication that has so far struggled to gain commercial traction.
From an investor standpoint, the Pasatru launch could add a high-margin, durable revenue stream to Regeneron’s rare-disease portfolio. While exact peak-sales estimates vary by source and are not yet reflected in consensus figures, the $1.4 million annual list price signals that even modest uptake could translate into meaningful revenue over time, especially if real-world data support broad clinical adoption within the small but severely affected FOP population.
Legal overhang from securities class action
Balancing the positive rare-disease news, investors must also digest a new securities class action lawsuit filed against Regeneron following negative developments in a Phase 3 melanoma trial. A legal advisory released on August 20, 2026 states that the lawsuit seeks to represent shareholders who purchased or otherwise acquired Regeneron common stock between August 1, 2025 and May 15, 2026, alleging damages tied to the company’s disclosures around the unsuccessful melanoma therapy. The class action notice emphasizes that the unexpected trial failure led to a sharp share-price decline and an estimated $11 billion market-cap loss at the time of the announcement.
A separate shareholder alert issued on the same date highlights a lead-plaintiff application deadline of September 14, 2026 for investors who believe they were harmed during the specified period. This reminder frames the case as focused on whether Regeneron’s communications adequately reflected the risk and status of the melanoma program before the Phase 3 setback became public.
The legal proceedings do not change Regeneron’s core operating metrics in the near term, but they introduce uncertainty around potential settlement costs and future disclosure obligations. For investors, the lawsuit reinforces the importance of monitoring how the company balances high-risk, high-reward oncology programs with its more established franchises, including ophthalmology and immunology, which historically have provided steady revenue growth.
Analyst valuation and performance context
Valuation-oriented commentary on August 20, 2026 suggests that Regeneron stock is trading modestly below one intrinsic value estimate despite recent volatility. A proprietary value metric puts the current share price at $834.47 and the estimated intrinsic value at $883.93, indicating the shares are 5.6% below that model’s fair-value mark. The valuation analysis notes that this modest undervaluation comes in the context of a year-to-date price gain supported by the Pasatru approval and ongoing strength in core franchises.
Consensus figures compiled in an institutional filing point to an average published price target of $801.70, which is 3.0% below the recent closing price of $826.64. The same filing cites a Moderate Buy consensus rating. The fact that the stock trades above the average target while one intrinsic-value model still labels it modestly undervalued illustrates how different methodologies can yield divergent views on upside, and underscores that expectations already embed a significant degree of success for current and future pipeline assets.
Institutional activity supports the notion that large investors remain engaged with Regeneron despite the legal overhang. Multiple filings dated August 21, 2026 report new positions or additional share purchases, with one adviser investing $4.37 million in Regeneron at recent prices. The institutional investment disclosure confirms that some professional investors view the current risk-reward profile as acceptable, given the company’s diversified pipeline and established revenue base.
Pasatru anchors Regeneron’s rare-disease push
Pasatru now sits at the center of Regeneron’s rare-disease strategy. The FOP indication is characterized by progressive abnormal bone formation, which can severely limit mobility and shorten life expectancy. Clinical data underpinning the FDA approval show that Pasatru reduced new heterotopic ossification lesions and flare-ups in adult FOP patients compared with control arms, forming the basis for its label. Coverage of the approval notes that Regeneron will compete against an existing therapy that has underperformed commercially, potentially leaving room for Pasatru to capture significant share if clinical differentiation proves compelling.
Strategically, Pasatru broadens Regeneron’s revenue mix beyond more common conditions like age-related macular degeneration and inflammatory diseases. The ultra-high per-patient pricing model seen in FOP reflects the economic reality of treating very small populations with complex biologic therapies. If realized utilization aligns with expectations, even a few hundred treated patients could translate into substantial annual revenue, contributing to earnings growth and strengthening the company’s position in rare disease markets.
At the same time, launching a $1.4 million-per-year therapy in an ultra-rare indication brings practical and ethical considerations around access, reimbursement, and long-term value. Payers and clinicians are likely to scrutinize real-world data on Pasatru’s ability to alter the course of FOP, and regulators may continue to monitor safety outcomes given the novelty of the approach. For shareholders, the key question is whether Pasatru can sustain high pricing and volume over time in a competitive environment, and how those outcomes feed into overall margin and cash-flow trends.
Closing view on Regeneron stock and current pricing
As of the close on August 20, 2026, Regeneron stock trades at $826.64 on the Cboe platform, with recent performance showing a 2.53% gain since the start of 2026 and a 6.95% advance over the past 12 months. The latest quote snapshot situates the shares modestly below one intrinsic-value estimate of $883.93 yet above the average published target of $801.70, highlighting a market that recognizes Regeneron’s pipeline potential while also pricing in legal and development risks.
Fact box
Company: Regeneron Pharmaceuticals Inc.
ISIN: US75886F1075
Ticker: REGN
Exchange: Nasdaq
Price (as of August 20, 2026, 3:55 p.m. ET): $826.64 USD
Market cap: $11.00 billion (as reported following the melanoma trial-related selloff)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
